Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives

Int J Mol Sci. 2015 Nov 30;16(12):28401-17. doi: 10.3390/ijms161226099.

Abstract

Cytidine 5'-diphosphocholine or citicoline is an endogenous compound that acts in the biosynthetic pathway of phospholipids of cell membranes, particularly phosphatidylcholine, and it is able to increase neurotrasmitters levels in the central nervous system. Citicoline has shown positive effects in Parkinson's disease and Alzheimer's disease, as well as in amblyopia. Glaucoma is a neurodegenerative disease currently considered a disease involving ocular and visual brain structures. Neuroprotection has been proposed as a valid therapeutic option for those patients progressing despite a well-controlled intraocular pressure, the main risk factor for the progression of the disease. The aim of this review is to critically summarize the current evidence about the effect of citicoline in glaucoma.

Keywords: citicoline; glaucoma; neuroprotection; retinal ganglion cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Central Nervous System / drug effects
  • Central Nervous System Diseases / drug therapy
  • Central Nervous System Diseases / etiology
  • Cytidine Diphosphate Choline / chemistry
  • Cytidine Diphosphate Choline / pharmacology*
  • Cytidine Diphosphate Choline / therapeutic use*
  • Eye / drug effects
  • Glaucoma / drug therapy*
  • Glaucoma / etiology
  • Glaucoma / metabolism
  • Humans
  • Intraocular Pressure / drug effects
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Ophthalmic Solutions / pharmacology
  • Ophthalmic Solutions / therapeutic use
  • Retinal Ganglion Cells / drug effects
  • Retinal Ganglion Cells / metabolism

Substances

  • Neuroprotective Agents
  • Ophthalmic Solutions
  • Cytidine Diphosphate Choline